“The Cuban biopharmaceutical industry will deliver a little more than six million doses to Minsap (both of Abdala and Sovereign vaccines) to accelerate the booster vaccination process, given the risk of the Omicron variant, said the president of BioCubaFarma,” according to a BioCubaFarma message on the social network Twitter.
“It is expected to complete all the doses necessary for the booster immunization to the entire population, before the end of January 2022,” underlined another message from the aforementioned scientific entity.
This week the national director of Epidemiology, Francisco Durán, reported the Caribbean nation accumulates six cases with the Ómicron variant of SARS-CoV-2, which causes Covid-19, but clarified that no contact with these people suffers from the coronavirus.
The lack of efficacy of existing vaccines against Covid-19, including ours, has not been proven, he said, adding that, apparently, Ómicron is highly contagious, although there are few details regarding its seriousness, critical condition and even death, so investigations continue.
Recently, the president of the Cuban Biotechnology and Pharmaceutical Industries Group, Eduardo Martínez, announced that the Caribbean country is developing specific immunogen designs against Omicron.